12th week of 2015 patent applcation highlights part 43 |
Patent application number | Title | Published |
20150079068 | FORMULATIONS OF RECOMBINANT FURIN - The present application provides stabilized formulations of furin (e.g., rfurin) containing a sugar, sugar alcohol, and/or non-ionic surfactant. As compared to non-stabilized compositions, the furin formulations disclosed herein retain greater amounts of furin activity and monomeric furin content, while reducing furin aggregation when stored and/or subjected to mechanical stress. Also provided are methods for stably diluting furin (e.g., rfurin) compositions. | 2015-03-19 |
20150079069 | METHODS FOR MODIFICATION OF TISSUES - Methods for modification of mechanical properties or a shape of a mammalian tissue, excluding scar, blood clot, fat; including a step of contacting the tissue with an isolated eukaryotic endopeptidase in an amount sufficient to cause a modification of mechanical properties of the tissue or its shape, but insufficient to cause degradation of the tissue's into incohesive parts, and to the use of eukaryotic endopeptidases for use in methods for treatment of the mammalian body. | 2015-03-19 |
20150079070 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES - Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided. | 2015-03-19 |
20150079071 | NON-CATALYTIC DOMAIN TARGETS IN MATRIX METALLOPROTEASE PROTEINS FOR CANCER THERAPIES - The present invention provides compositions and methods for inhibiting MMPs, especially MMP-3, MMP-9 and MMP-14. The invention relates to the field of diagnostic and prognostic methods of human cancers, especially breast cancer and the field of matrix metalloproteases, as targets for diagnostics and therapeutics. | 2015-03-19 |
20150079072 | Assays to Monitor Bleeding Disorders - The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample | 2015-03-19 |
20150079073 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. | 2015-03-19 |
20150079074 | Antibody Formulations And Methods - The invention provides antibody formulations and methods useful for prophylaxis or treatment of synucleinopathies, including Parkinson's disease. | 2015-03-19 |
20150079075 | Anti-CD11A Antibodies and Uses Thereof - Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to CD11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of HIV infection or AIDS) in a subject that has an HIV infection or AIDS that include administering at least one of the antibodies or antigen-binding fragments to the subject. Also provided are methods of crosslinking CD11a on the surface of a cell that include contacting the cell with at least one of the antibodies or antigen-binding fragments. Also provided are compositions (e.g., pharmaceutical compositions) containing at least one of the antibodies or antigen-binding fragments. | 2015-03-19 |
20150079076 | IDENTIFICATION OF NON-RESPONDERS TO HER2 INHIBITORS - The present invention relates to means and methods for the identification of non-responders to a HER2 inhibitor, whereby one or more mutations in exon 9 of Phosphoinositol-3 kinase (PIK3CA) indicate non-responsiveness. | 2015-03-19 |
20150079077 | METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS - The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others). | 2015-03-19 |
20150079078 | BIOMARKERS FOR TRIPLE NEGATIVE BREAST CANCER - The present invention relates to biomarkers that are useful in the prognosis of triple negative breast cancer patients. The biomarkers may be used to select treatment and to determine whether a treatment is effective or not. The biomarkers may also be used to select novel treatments and to screen for new potential compounds that may treat the triple negative breast cancer. | 2015-03-19 |
20150079079 | Methods and Compositions for Treatment of Chlamydial Infection and Related Diseases and Disorders - The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject. | 2015-03-19 |
20150079080 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 2015-03-19 |
20150079081 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE - Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. | 2015-03-19 |
20150079082 | OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2015-03-19 |
20150079083 | Alpha B-Crystallin as a Therapy for Ischemia or Inflammation - The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease. | 2015-03-19 |
20150079084 | PROTEIN INHIBITORS TO COMPLEMENT AND VEGF PATHWAYS AND METHODS OF USE THEREOF - The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins. | 2015-03-19 |
20150079085 | METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION - The invention relates to methods of modulating immune responses in a subject such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them. | 2015-03-19 |
20150079086 | Methods for treatment of brain injury utilizing biologics - A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included. | 2015-03-19 |
20150079087 | VEGF ANTAGONIST FORMULATIONS - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 2015-03-19 |
20150079088 | MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME - The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 2015-03-19 |
20150079089 | EMP2 REGULATES ANGIOGENESIS IN CANCER CELLS THROUGH INDUCTION OF VEGF - Disclosed herein are methods and compositions for modulating neovascularization. The disclosed compositions find particular use in the treatment of uterine cancers, specifically endometrial cancers. | 2015-03-19 |
20150079090 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE - The present invention relates to a therapeutic agent for inflammation in which histone is involved, the agent comprising a monoclonal antibody or an antigen binding fragment thereof which binds to a peptide consisting of an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO:1) or a conjugate of the peptide and a pharmaceutically acceptable carrier. | 2015-03-19 |
20150079091 | MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES - Mutations in calreticulin are discovered to be linked to myeloid malignancies. Disclosed are genomic sequences, cDNA sequences, mRNA sequences and protein sequences of mutant calreticulin that are linked to myeloid malignancies. Also disclosed are methods for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also disclosed are related compositions, kits and methods, including the medical use of inhibitors of mutant calreticulin. | 2015-03-19 |
20150079092 | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ra) - 173 - Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD. | 2015-03-19 |
20150079093 | DUAL ANTIGEN-INDUCED BIPARTITE FUNCTIONAL COMPLEMENTATION - The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “A” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides. | 2015-03-19 |
20150079094 | Functional Peptide Analogs of PEDF - The invention provides compositions and methods relating to bioactive peptide analogs of PEDF. | 2015-03-19 |
20150079095 | PREVENTON, TREATMENT AND DIAGNOSIS OF P. GINGIVALIS INFECTION - The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of | 2015-03-19 |
20150079096 | METHOD FOR THE TREATMENT OF AMYLOIDOSES - The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer's disease in a subject in need thereof, characterized in that it comprises administering an inhibitor of the interaction between Aβ globulomer and the P/Q type voltage-gated presynaptic calcium channel to said subject. | 2015-03-19 |
20150079097 | S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF - The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof. | 2015-03-19 |
20150079098 | Method of treating cancer - A method is described to treat cancer by extracorporeally treating a bodily fluid of a patient. A patient's body fluid is treated extracorporeally using a moiety that targets an antigen in the bodily fluid. The treatment can include applying an anti-angiogenesis, anti-tumorigenesis, anti-metastasis, or chemotherapeutic treatment to at least one antigen in the bodily fluid. The moiety facilitates removal of the antigen. The cleansed body fluid is then returned to the patient. | 2015-03-19 |
20150079099 | Anti-RANTES Antibodies - The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder. | 2015-03-19 |
20150079100 | METHODS OF TREATMENTS USING CTLA-4 ANTIBODIES - In certain embodiments, the present invention, the present invention provides a method of treating a cancer in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-CTLA4 antibody; (b) detecting the level of the anti-CTLA4 antibody in a sample of the subject; and (c) increasing the dosage of the anti-CTLA4 antibody in the subject if the level of the anti-CTLA4 antibody from step (b) is below a threshold exposure level, such that the cancer is treated. | 2015-03-19 |
20150079101 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 2015-03-19 |
20150079102 | PURIFIED ANTIBODY COMPOSITION - The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. | 2015-03-19 |
20150079103 | PURIFIED ANTIBODY COMPOSITION - The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. | 2015-03-19 |
20150079104 | Methods For Inhibiting The Binding Of Endosialin To Ligands - The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro. | 2015-03-19 |
20150079105 | TREATMENT OF ACUTE INFLAMMATION IN THE RESPIRATORY TRACT - This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of acute inflammation of the respiratory tract, especially acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Levels of CCL7 have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of CCL7 and/or other members of the PAR1-CCL7 axis, or CCL2 can be used to prevent and/or treat these conditions. | 2015-03-19 |
20150079106 | ANTI-NEOPLASTIC USES OF ARTEMIN ANTAGONISTS - The invention relates to methods for the prophylaxis and treatment of breast cancer using one or more antagonists of artemin function, such as anti-artemin polynucleotides or anti-artemin antibodies and antibody fragments, and uses of these antagonists. In particular, the invention relates to the resensitisation of therapy-resistance breast cancer cells to anti-cancer therapies by antagonism of artemin functionality. | 2015-03-19 |
20150079107 | AGENTS AND METHODS FOR TREATING AND PREVENTING SEBORRHEIC KERATOSIS - Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject. | 2015-03-19 |
20150079108 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY - The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2. | 2015-03-19 |
20150079109 | Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics - Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions. | 2015-03-19 |
20150079110 | REGENERATION OF INNER EAR CELLS - The invention provides compositions and methods for treating or preventing hearing loss in a subject. The method comprises administering to the subject in need thereof, at least Myc or an agent that increases the expression of Myc in an inner ear organ, or associated neural structures, of the subject so as to treat or prevent the hearing loss. | 2015-03-19 |
20150079111 | MECHANISM, DIAGNOSTIC, AND TREATMENTS FOR COMPLICATIONS OF RENAL FAILURE - Mechanisms for complications of renal failure and processes for treating the same are disclosed. They include contacting a biological fluid (e.g. blood) with a filter body, the filter body having immobilized thereon either a CD36 receptor or a CD36 receptor fragment or a SCARB1 receptor or a SCARB1 receptor fragment, the blood having a reduced quantity of oxidatively modified proteins after contacting the filter body. They also include administering an antagonist drug to a patient that blocks the binding activity of the RAGE receptor or the CD36 receptor or the SCARB1 receptor. Diagnostic methods are also provided. | 2015-03-19 |
20150079112 | USE OF AN ANTI-ANG2 ANTIBODY - A method of preventing or treating cancer using an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes to a Tie2 receptor while bound with Ang2. | 2015-03-19 |
20150079113 | MENA AND ALPHA5 INTEGRIN INTERACTION - Methods are provided for treating invasion of a tumor or metastasis of a tumor in a subject comprising administering to the subject an agent which inhibits the interaction of Mena with an alpha5 integrin. Assays for identifying agents that inhibit interaction of Mena with an alpha5 integrin are also provided. | 2015-03-19 |
20150079114 | DR5 LIGAND DRUG CONJUGATES - Ligand Drug Conjugates are provided having a DRS binding moiety attached via linking groups andor spacers to a therapeutic agent that are effective in treatment of various cancers. In some embodiments, the Ligand Drug Conjugate has the formula: L-(LU-D)p, where L is a Ligand unit, LU is a Linker unit and D is a Drug unit (or cytotoxic agent). The subscript p is an integer of from 1 to 20. Accordingly, the Ligand Drug Conjugates comprise a Ligand unit covalently linked to at least one Drug unit. The Drug units can be covalently linked directly or via a Linker unit (-LU-). The Ligand unit is a DR5 binding agent, such as an anti-DRS antibody. | 2015-03-19 |
20150079115 | Compositions and Methods for Preventing or Relieving Symptoms of Infections - Food products and/or pharmaceutical preparations including (i) viral neutralizing antibodies or antibody fragments anchored to a probiotic microorganism and (ii) a carrier medium for delivering the viral neutralizing antibodies or antibody fragments anchored to probiotic microorganisms to the gut of a mammal. Also provided are methods of making food products and/or pharmaceutical preparations, which can be used to treat existing viral infections or prevent the spread or transmission of viral infection. | 2015-03-19 |
20150079116 | DIAGNOSTIC TOOLS FOR RESPONSE TO 6-THIOPURINE THERAPY - NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein. | 2015-03-19 |
20150079117 | Paramyxovirus Immunogens and Related Materials and Methods - The present invention includes methyltransferase (MTase)-defective recombinant viruses as live vaccine candidates for human metapneumovirus (hMPV), human respiratory syncytial virus (hRSV), and human parainfluenza virus type 3 (PIV3). Here the inventors provide the technical description for generating MTase-defective paramyxoviruses useful as immunogens, as well Cas related materials and methods. | 2015-03-19 |
20150079118 | MicroRNA Treatment for Asthma - This invention relates to a composition for modifying the activity of microRNA-mediated regulation of mRNA in a cell, wherein the composition comprises: two or more compounds capable of blocking two or more microRNA molecules from binding to the same target mRNA, wherein the two or more microRNA molecules are different in sequence or structure relative to each other. In particular, compositions for use in the treatment of asthma and methods of prevention or treatment of asthma. | 2015-03-19 |
20150079119 | IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER - Compositions, methods, systems, apparatus and/or articles of manufacture are disclosed for reducing the susceptibility of a population and/or members thereof to cancer, which may include anti-cancer vaccines, components thereof which may include novopeptides, and methods relating thereto. | 2015-03-19 |
20150079120 | DNA SEQUENCE AND PREPARATION OF GRASS POLLEN ALLERGEN PHL P4 BY RECOMBINANT METHODS - The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the | 2015-03-19 |
20150079121 | Human Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same - Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acid are disclosed that comprise the sequences that encodes consensus RSV F protein or immunogenic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Method of preventing RSV infection and methods of treating individuals infected with RSV are disclosed. | 2015-03-19 |
20150079122 | HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS - A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine. | 2015-03-19 |
20150079123 | LIVE, ATTENUATED RUBELLA VECTOR TO EXPRESS VACCINE ANTIGENS - Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) without an in-frame deletion, a rubella structural protein ORF, and a heterologous antigenic insert. In one example, the heterologous antigenic insert is positioned within the rubella structural protein ORF. In some examples, the heterologous antigenic insert is positioned in the rubella structural protein ORF in between a gene encoding structural protein E2 and a gene encoding structural protein E1. Exemplary antigenic inserts include HIV, SIV, RSV or hepatitis B surface antigens. In some examples, the HIV antigenic insert is a Gag antigenic insert, a gp41 antigenic insert or a gp120 antigenic insert. Also disclosed are uses of the isolated rubella viral vector, such as to induce an immune response to a particular virus, such as HIV-1, testing sensitivity to neutralizing antibodies, or screening antiviral drugs (such as protease inhibitors). | 2015-03-19 |
20150079124 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 2015-03-19 |
20150079125 | VACCINE - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from | 2015-03-19 |
20150079126 | Plasmodium falciparum antigens - The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against | 2015-03-19 |
20150079127 | CANINE BABESIOSIS VACCINE ANTIGEN - The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine | 2015-03-19 |
20150079128 | CHINESE MEDICINAL FORMULATION FOR TREATING INFLAMMATORY BOWEL DISEASE AND THE PREPARATION THEREOF - This invention relates to a Chinese medicinal formulation for the treatment of inflammatory bowel diseases, and a method of preparation thereof. The formulation comprises herbal components selected from a group consisting of Radix Codonopsis (Dangshen), Rhizoma Atractylodis Macrocephalae (Bai Zhu), Sclerotium Poriae Cocos (Fu Ling), Rhizoma Zingiberis Officinalis (Gan Jiang), Radix Paeoniae Alba (Bai Shao) and Rhizoma Coptidis (Huanglian). | 2015-03-19 |
20150079129 | VACCINE - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from | 2015-03-19 |
20150079130 | ADJUVANT SYSTEM FOR ORAL VACCINE ADMINISTRATION - The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced T | 2015-03-19 |
20150079131 | Prevention of Inflammatory Disorders in Domestic Non-Human Mammals - The present invention regards use of a bacterial superantigen for administration onto the mucous membrane of a domestic non-human mammal for the prevention of inflammatory disorder, such as allergies, autoimmune and inflammatory diseases. | 2015-03-19 |
20150079132 | EVOKING PROTECTION AGAINST STREPTOTOCCUS PNEUMONIAE INCORPORATING B-CELL AND T-CELL PNEUMOCOCCAL PROTEIN ANTIGENS AND PNEUMOCOCCAL POLYSACCHARIDES DELIVERED CONCOMITANTLY - This disclosure is directed to compositions that combine the polysaccharide-specific antibody protection afforded by the conventional vaccines through carrier effects provided by one or more pneumococcal common T-cell antigen(s) together with | 2015-03-19 |
20150079133 | METHOD OF VACCINE DELIVERY VIA MICRONEEDLE ARRAYS - A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer. | 2015-03-19 |
20150079134 | TREATMENT TO PROMOTE WOUND HEALING - The invention relates to a field of tissue repair and regeneration. More particularly, the invention relates to a composition for promoting cutaneous wound healing. In one embodiment, the composition is composed of one or more metazoan parasites or a mimic thereof sufficient to promote helminth-induced type-2 immune response. Preferably, the composition contains | 2015-03-19 |
20150079135 | METHODS FOR TREATING AND MONITORING THE STATUS OF CANCER - Provided herein are methods for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a peptide derived from the EphA2 protein and/or the IL-13Rα2 protein and monitoring the amount of cancer stem cells in said subject. Also provided herein are methods for monitoring the efficacy of an EphA2 peptide-based cancer treatment or an IL-13Rα2 peptide-based cancer treatment in a patient with cancer, comprising monitoring the amount of cancer stem cells in said subject prior to, during, and/or following cancer treatment of a patient. | 2015-03-19 |
20150079136 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS OF DIRECT THROMBIN INHIBITORS - The present invention relates to controlled release pharmaceutical formulations of direct thrombin inhibitors and processes for preparing such compositions. Particularly the present invention relates to oral controlled release pharmaceutical compositions comprising dabigatran etexilate or pharmaceutically acceptable salts thereof. | 2015-03-19 |
20150079137 | EXOPOLYSACCHARIDE FOR THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR NAILS - Exopolysaccharide of a bacterial strain for its use in treatment and/or care of the skin, mucous membranes, hair and/or nails, as well as its cosmetic and/or dermopharmaceutical compositions. In particular, for the aging of skin and in particular for the treatment and/or prevention of wrinkles. | 2015-03-19 |
20150079138 | UV Protection Agent Based on Bismuth Oxychloride - Provided herein is a Bismuth inorganic salt, specifically, Bismuth Oxychloride useful as a sun protection agent, and to the synthesis methods to obtain optimized Bismuth Oxychloride with specific photoprotecting features ensuring optimum stability, effectiveness and safety for the protection against skin and/or hair, and/or facial hair, and/or body hair damage caused by UV solar radiation. Furthermore, different compositions with effective and safe concentrations of Bismuth Oxychloride are described. These compositions exhibit protection values above those commonly obtained from organic and inorganic agents known in the state of the art, all along the ultraviolet spectrum (290 to 400 nm). This physically and chemically characterized compound, with critical wavelengths above 380 nm, is a “broad spectrum” sunscreen. | 2015-03-19 |
20150079139 | HAIR PROCESSING AGENT COMPOSITION, AND HAIR PROCESSING AGENT COMPOSITION FOR DYEING HAIR . . . . - There is provided a hair procession agent composition including: 22% by mass or less of inorganic particles having an average particle size of primary particles of 1 nm to 1 μm, and an oil-soluble dispersant. | 2015-03-19 |
20150079140 | LOW-VOC CLEANING SUBSTRATES AND COMPOSITIONS - A cleaning composition for sanitizing and/or disinfecting hard surfaces, comprising: a cationic biocide, surfactant and low levels of VOC solvents. The cleaning composition is adapted to clean a variety of hard surfaces without leaving behind a visible residue and creates low levels of streaking and filming on the treated surface. The cleaning composition contains less than 5% by weight of VOCs. The cleaning composition may be used alone as a liquid or spray formulation or in combination with a substrate, for example, a pre-loaded cleaning wipe. | 2015-03-19 |
20150079141 | Chelated Metal Oxide Gel Compositions - Described is a homogeneous gel composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising; a combination of a stable and homogeneous aqueous and/or polyol solution based chelated metal oxide liquid complex suspension and a gel composition free of chelated metal oxides comprising water, polyquaternium, glycerine and hyaluronic acid, wherein the homogeneous gel composition contains chelated metal oxide particles homogeneously suspended in the homogeneous gel composition such that a concentration of the chelated metal oxide particles contained within the homogeneous gel are in a concentration of at least 0.001 weight percent. | 2015-03-19 |
20150079142 | DEVICES AND METHODS FOR PREVENTING PLATELET ACTIVATION - Methods for inhibiting a biomaterial-associated thrombotic event comprise reducing the number of platelets that bind to the biomaterial, or inhibiting platelet activation, by attaching CD47 or the Ig domain thereof to the surface of the biomaterial. Methods of the present invention inhibit thrombi formation on or near a biomaterial that is on the surface of an implant, medical device, tube, or therapeutic delivery vehicle. Also provided are kits for practicing these methods and the modified biomaterials. | 2015-03-19 |
20150079143 | THREE-DIMENSIONAL SCAFFOLDS FOR TISSUE ENGINEERING MADE BY PROCESSING COMPLEX EXTRACTS OF NATURAL EXTRACELLULAR MATRICES - Methods of making a biologically active three-dimensional scaffold capable of supporting growth and differentiation of a cell are described. Biologically active three-dimensional scaffold made by the methods of the invention and an engineered tissue made from the scaffolds are described. Fibers of desired porosity can be obtained from non-structural ECM by lyophilization and/or electrospinning which can be useful for numerous tissue engineering applications requiring complex scaffolds, such as wound healing, artificial skin (burns), soft tissue replacement/repair and spinal cord injury. | 2015-03-19 |
20150079144 | ANTI-INFECTIVE LUBRICANT FOR MEDICAL DEVICES AND METHODS FOR PREPARING THE SAME - A lubricious antiseptic coating material containing various solvents to achieve mutual miscibility and provide a generally homogenous product. A coating material is provided having an antipathogenic agent and a solvent for dissolving the same. The coating further includes a lubricious agent and a solvent for dissolving the same. Thus, the coating material contains antiseptic and lubricious properties suitable for application to a desired surface to kill or inhibit the growth of pathogens known to cause catheter related bloodstream infections. | 2015-03-19 |
20150079145 | PROTEIN STABILIZATION FORMULATIONS - The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants. | 2015-03-19 |
20150079146 | BIOACTIVE GLASS FIBER MESH FOR REPAIR OF HARD TISSUES - The invention relates to the use of a bioactive glass material. For example, an autograft chip is wrapped in bioactive glass material for the treatment of bone injuries and bone defects in the body. The material can be in one or more of several forms, such as fibers, a fiber mesh, a sheet, or another shape. The material can be applied to hard tissues, such as bone. | 2015-03-19 |
20150079147 | FIBER WADDING FOR FILLING BONE DEFECTS - A fiber wadding for filling bone defects having a flocculent three-dimensional structure is disclosed. The fiber wadding includes a plurality of fibers that contain a biodegradable resin as a principal component and a siloxane. Outside diameter of the plurality of fibers of the wadding is from about 0.05 μm to about 30 μm. Bulk density of the fiber wadding is about 0.005-0.3 g/cm | 2015-03-19 |
20150079148 | Thixotropic Processing of Magnesium Composites with a Nanoparticles-Haloed Grain Structure for Biomedical Implant Applications - In described embodiments, the present invention includes a magnesium-based composite material formed from a plurality of α-phase magnesium grains; and a β-alloy phase comprising magnesium and nano-diamond and/or and phosphate containing nanoparticles, the β-alloy phase surrounding each of the plurality of magnesium grains. A method of manufacturing a composite material is also disclosed. | 2015-03-19 |
20150079149 | DISSOLVABLE DIETARY SUPPLEMENT STRIP AND METHODS FOR USING THE SAME - A strip, which is both edible and dissolvable, is provided comprising a film and a dosage of at least 2% of the reference daily intake (RDI) of at least one dietary supplement for malnutrition or to prevent/treat alcohol induced hangovers. A method for treating malnutrition and/or preventing and treating alcohol-induced hangovers using a dissolvable orally administered strip. | 2015-03-19 |
20150079151 | BIODEGRADABLE COMPOSITIONS HAVING PRESSURE SENSITIVE ADHESIVE PROPERTIES - A composition comprising the reaction product of (a) an isocyanate group-containing component having an average functionality of at least 2; and (b) an active hydrogen group-containing component having an average functionality of at least 2. The composition is biodegradable, a solid at 22° C. and below, and has pressure sensitive adhesive properties at a temperature of 37° C. and relative humidity of 100%. The composition may be used to adhere polymer meshes or films to biological tissue. | 2015-03-19 |
20150079152 | COMPOSITION AND DRESSING FOR WOUND TREATMENT - The invention provides methods and compositions for wound treatment and/or blood clot formation, e.g., arresting the flow of blood from an open wound. The methods and compositions provide for promoting and accelerating wound healing and optionally provide for inhibition of microbial infection and/or a local analgesic effect. | 2015-03-19 |
20150079153 | Cell Suspension and Use Thereof - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration. | 2015-03-19 |
20150079154 | MEDICAMENT FOR TREATMENT OF LIVER CANCER - The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer. | 2015-03-19 |
20150079155 | Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood - This invention concerns a liposome comprising lipids and at least one active ingredient, wherein at least one of the lipids is a cationic lipid; said liposome exhibiting a net positive charge at physiological conditions at which said liposome preferentially adheres to monocytes in freshly drawn blood when compared to adherence to granulocytes, T-lymphocytes, B-lymphocytes and/or NK cells in freshly drawn blood, to a lipid-based pharmaceutical composition comprising said liposomes and their use in monocytic associated prophylaxis, treatment or amelioration of a condition such as cancer, an infectious disease, an inflammatory disease, an autoimmune disease or allergy. | 2015-03-19 |
20150079156 | LIPOSOMAL DELIVERY SYSTEM - The present invention is directed to a liposomal delivery system comprising defined lipid components, including dimethyldioctadecylammonium and other lipid components and a stabilizing agent, which may be used in the delivery of bioactive agents to a subject in need thereof. The liposomal delivery system of the invention provide improvements in terms of delivery and stability. Ideally, the liposomal delivery system is used as a vaccine or drug/medicament delivery system although other bioactive agents may be delivered. | 2015-03-19 |
20150079157 | COMPOSITION COMPRISING PURINE DERIVATIVES OR SALT THEREOF FOR PREVENTING OR TREATING ATOPIC DERMATITIS - The present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt as an active ingredient. And also, the present invention provides a cosmetic composition for improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt; and a food (i.e., a functional food) for preventing or improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt. | 2015-03-19 |
20150079158 | METHOD TO STABILIZE LIPOSOME EMULSIONS FOR BIOCIDAL DELIVERY - An improved stabilized biocidal delivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex bio-film matrices through the use of liposome emulsion in an ethoxylated compound, thereby removing the bio-fouling in industrial water bearing systems, including piping, heat exchangers, condensers, filtration systems and fluid storage tanks. The liposome emulsion is comprised of a vesicle encapsulated biocide that is stabilized against chemical and heat degradation over longer periods of time than previously possible through the incorporation of one or more stabilizer compounds. | 2015-03-19 |
20150079159 | Formulations and Methods for Delaying Onset of Chronic Neuropathic Pain - A dosing regimen for formulations that contain a therapeutic dosage of a site 1 sodium channel blocker, where the dosing regimen provides a prolonged nerve block and is in an effective amount to delay the onset of neuropathic pain, such as hyperalgesia and/or allodynia, for at least one week, and preferably longer at the site, and preferably the region (e.g. entire limb), where the nerve block was applied. The site 1 sodium channel blocker is preferably saxitoxin (STX), preferably in combination with a corticosteroid, preferably dexamethasone. In a preferred embodiment, liposomes are included in the formulation as a controlled release system, producing prolonged duration of block without systemic toxicity. As demonstrated by the examples, encapsulating STX in a controlled release system, such as liposomes, preferably also including a corticosteroid, and administering in suitable dosing regimen to achieve a prolonged nerve block without systemic toxicity, delays the onset of hyperalgesia. | 2015-03-19 |
20150079160 | NON-IMPLANTABLE MEDICAL DEVICE COATED WITH NANO-CARRIERS FOR DELIVERING ONE OR MORE DRUGS TO A BODY SITE - A drug-delivering medical device for delivering a drug to a target site in a human body is disclosed. The drug-delivering medical device may have a hydrophilic surface, with one or more portions of the hydrophilic surface coated with one or more nano-carriers bearing one or more drugs. Each nano-carrier may include a drug surrounded by an encapsulating medium. As the drug is surrounded by the encapsulating medium, the surface of each nano-carrier can be devoid of the respective drug. A non-implantable medical device coated with nano-carriers can deliver one or more drugs to a blood vessel, organ cavity, sac, capsule, lining, layer, coating, membrane, connective tissue, fluid surrounding an organ, and so forth. | 2015-03-19 |
20150079161 | METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia or neurons, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2. | 2015-03-19 |
20150079162 | CERIA NANOCOMPLEX, PHARMACEUTICAL COMPOSITION COMPRISING SAID CERIA NANOCOMPLEX, AND METHOD FOR PREPARING SAME - The present invention relates to ceria nanocomposite, pharmaceutical composition comprising the ceria nanocomposite, and method for preparing same. More particularly, the present invention is directed to a ceria nanocomposite comprising a ceria nanoparticle, wherein the ceria nanoparticle is encapsulated with a surfactant and the surfactant is encapsulated with polyethylene glycol-phospholipid, pharmaceutical composition for preventing or treating ischemic stroke comprising thereof and method for preparing the same. | 2015-03-19 |
20150079163 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE - The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions. | 2015-03-19 |
20150079164 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND VITAMIN D FOR ACNE VULGARIS AND/OR ECZEMA, AND METHODS AND USES THEREOF - The present disclosure relates to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with acne and/or eczema (dermatitis). | 2015-03-19 |
20150079165 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 - Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D | 2015-03-19 |
20150079166 | Solid Compositions Comprising a Salt of Aminocarboxylic Acid - The present disclosure provides solid compositions comprising a stabilized salt of aminocarboxylic acid. Pharmaceutical compositions comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate in combination with appropriate additives are also provided. | 2015-03-19 |
20150079167 | ENCASED-PELLET TABLETS - An encased-pellet tablet for an active pharmaceutical ingredient comprises an excipient layer on the outside and an inner core that is surrounded by the excipient layer. The inner core contains a plurality of coated pellets, and the coated pellets comprise pellets of the active pharmaceutical ingredient coated with a pellet coating. The excipient layer contains from about 1 wt. % to about 20 wt. % of at least one cushioning agent selected from polyhydroxyl compounds. A method for manufacturing the encased-pellet tablets involves compressing an excipient material to form a first layer; compressing a plurality of coated pellets containing an API on said first layer to form an inner core thereon and compressing additional excipient material around an exposed portion of said inner core thereby surrounding said inner core with excipient material. | 2015-03-19 |
20150079168 | USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS - Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed. | 2015-03-19 |